The potential role of chemokines in alzheimer's disease pathogenesis

American Journal of Alzheimer's Disease and other Dementias

Volumn 29, Issue 5, 2014, Pages 415-425

  Azizi, Gholamreza ^a   Khannazer, Nikoo ^b   Mirshafiey, Abbas ^c  

^a ALBORZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF TEHRAN   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Alzheimer's disease; CCL2; CCL3; CCL5; chemokine; CX3CL1; CXCL12; CXCL8; inflammation; MIF; neurodegeneration

Indexed keywords

CHEMOKINE; FRACTALKINE; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; STROMAL CELL DERIVED FACTOR 1;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANTIINFLAMMATORY ACTIVITY; BIOLOGICAL ACTIVITY; CELL ACTIVATION; CELL INTERACTION; GLIA CELL; HUMAN; IMMUNOPATHOLOGY; INFLAMMATORY CELL; MEMORY DISORDER; NERVE CELL; NERVE CELL DEGENERATION; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NEUROMODULATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; REVIEW; SENILE PLAQUE; COMPLICATION; IMMUNOLOGY; INFLAMMATION;

ALZHEIMER DISEASE; CHEMOKINES; HUMANS; INFLAMMATION;

EID: 84904414201     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317513518651     Document Type: Review

References (116)

1. Passos GF, Figueiredo CP, Prediger RD, et al. Involvement of phosphoinositide 3-kinase gamma in the neuro-inflammatory response and cognitive impairments induced by beta-amyloid 1-40 peptide in mice. Brain Behav Immun. 2010 ; 24 (3). 493-501
2. Farfara D, Lifshitz V, Frenkel D. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J Cell Mol Med. 2008 ; 12 (3). 762-780
3. Higuchi M, Hatta K, Honma T, et al. Association between altered systemic inflammatory interleukin-1beta and natural killer cell activity and subsequently agitation in patients with Alzheimer disease. Int J Geriatr Psychiatry. 2010 ; 25 (6). 604-611
4. González-Scarano F, Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci. 1999 ; 22: 219-240
5. Heneka MT, O'Banion MK, Terwel D, Kummer MP. Neuroinflammatory processes in Alzheimer's disease. J Neural Transm. 2010 ; 117 (8). 919-947
6. Rubio-Perez JM, Morillas-Ruiz JM. A review: inflammatory process in Alzheimer's disease, role of cytokines. ScientificWorldJournal. 2012 ; 2012: 756357
7. Fernandez EJ, Lolis E. Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol. 2002 ; 42: 469-499
8. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000 ; 12 (2). 121-127
9. Mélik-Parsadaniantz S, Rostène W. Chemokines and neuromodulation. J Neuroimmunol. 2008 ; 198 (1-2). 62-68
10. Rollins BJ. Chemokines. Blood. 1997 ; 90 (3). 909-928
11. Murdoch C, Finn A. Chemokine receptors and their role in inflammation and infectious diseases. Blood. 2000 ; 95 (10). 3032-3043
12. Moser B, Willimann K. Chemokines: role in inflammation and immune surveillance. Ann Rheum Dis. 2004 ; 63 (suppl 2). ii84 - ii89
13. Holman DW, Klein RS, Ransohoff RM. Ransohoff, The blood-brain barrier, chemokines and multiple sclerosis. Biochim Biophys Acta. 2011 ; 1812 (2). 220-230
14. Savarin-Vuaillat C, Ransohoff RM. Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce?. Neurotherapeutics. 2007 ; 4 (4). 590-601
15. Conductier G, Blondeau N, Guyon A, Nahon JL, Rovère C. The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J Neuroimmunol. 2010 ; 224 (1-2). 93-100
16. Ruan L, Kong Y, Wang JM, Le Y. Chemoattractants and receptors in Alzheimer's disease. Front Biosci (Schol Ed). 2010 ; 2: 504-514
17. Xia MQ, Hyman BT. Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J Neurovirol. 1999 ; 5 (1). 32-41
18. Mines M, Ding Y, Fan GH. The many roles of chemokine receptors in neurodegenerative disorders: emerging new therapeutical strategies. Curr Med Chem. 2007 ; 14 (23). 2456-2470
19. El Khoury J, Luster AD. Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications. Trends Pharmacol Sci. 2008 ; 29 (12). 626-632
20. Gemechu JM, Bentivoglio M. T Cell recruitment in the brain during normal aging. Front Cell Neurosci. 2012 ; 6: 38
21. Chabot S, Williams G, Yong VW. Microglial production of TNF-alpha is induced by activated T lymphocytes. Involvement of VLA-4 and inhibition by interferonbeta-1b. J Clin Invest. 1997 ; 100 (3). 604-612
22. Chabot S, Williams G, Hamilton M, Sutherland G, Yong VW. Mechanisms of IL-10 production in human microglia-T cell interaction. J Immunol. 1999 ; 162 (11). 6819-6128
23. Giuliani F, Hader W, Yong VW. Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction. J Leukoc Biol. 2005 ; 78 (1). 135-1543
24. Bromley SK, Peterson DA, Gunn MD, Dustin ML. Cutting edge: hierarchy of chemokine receptor and TCR signals regulating T cell migration and proliferation. J Immunol. 2000 ; 165 (1). 15-19
25. Duan RS, Yang X, Chen ZG, et al. Decreased fractalkine and increased IP-10 expression in aged brain of APP(swe) transgenic mice. Neurochem Res. 2008 ; 33 (6). 1085-1089
26. Popp J, Bacher M, Kölsch H, et al. Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease. J Psychiatr Res. 2009 ; 43 (8). 749-753
27. Corrêa JD, Starling D, Teixeira AL, Caramelli P, Silva TA. Chemokines in CSF of Alzheimer's disease patients. Arq Neuropsiquiatr. 2011 ; 69 (3). 455-459
28. Galimberti D, Scarpini E. Inflammation and oxidative damage in Alzheimer's disease: friend or foe?. Front Biosci (Schol Ed). 2011 ; 3: 252-266
29. Galimberti D, Schoonenboom N, Scheltens P, et al. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol. 2006 ; 63 (4). 538-543
30. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000 ; 21 (3). 383-421
31. Goldeck D, Larbi A, Pellicanó M, et al. Enhanced chemokine receptor expression on leukocytes of patients with Alzheimer's disease. PLoS One. 2013 ; 8 (6). e66664
32. Olson L, Humpel C. Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimer's disease and mild cognitive impairment. Exp Gerontol. 2010 ; 45 (1). 41-46
33. Rosén C, Hansson O, Blennow K, Zetterberg H. Fluid biomarkers in Alzheimer's disease - current concepts. Mol Neurodegener. 2013 ; 8: 20
34. Tarkowski E, Blennow K, Wallin A, Tarkowski A. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol. 1999 ; 19 (4). 223-230
35. Sokolova A, Hill MD, Rahimi F, Warden LA, Halliday GM, Shepherd CE. Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathol. 2009 ; 19 (3). 392-398
36. Alsadany MA, Shehata HH, Mohamad MI, Mahfouz RG. Histone deacetylases enzyme, copper, and IL-8 levels in patients with Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2013 ; 28 (1). 54-61
37. Tarawneh R, D'Angelo G, Macy E, et al. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol. 2011 ; 70 (2). 274-285
38. Thorsell A, Bjerke M, Gobom J, et al. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. Brain Res. 2010 ; 1362: 13-22
39. Bonneh-Barkay D, Bissel SJ, Wang G, et al. YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. Am J Pathol. 2008 ; 173 (1). 130-143
40. Montine TJ, Markesbery WR, Morrow JD, Roberts LJ. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann Neurol. 1998 ; 44 (3). 410-413
41. Blasko I, Lederer W, Oberbauer H, et al. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement Geriatr Cogn Disord. 2006 ; 21 (1). 9-15
42. Hickman SE, El Khoury J. Mechanisms of mononuclear phagocyte recruitment in Alzheimer's disease. CNS Neurol Disord Drug Targets. 2010 ; 9 (2). 168-173
43. Zhang R, Miller RG, Madison C, et al. Systemic immune system alterations in early stages of Alzheimer's disease. J Neuroimmunol. 2013 ; 256 (1-2). 38-42
44. Peterson PK, Hu S, Salak-Johnson J, Molitor TW, Chao CC. Differential production of and migratory response to beta chemokines by human microglia and astrocytes. J Infect Dis. 1997 ; 175 (2). 478-481
45. Porcellini E, Ianni M, Carbone I, Franceschi M, Licastro F. Monocyte chemoattractant protein-1 promoter polymorphism and plasma levels in Alzheimer's disease. Immun Ageing. 2013 ; 10 (1). 6
46. Ishizuka K, Kimura T, Igata-yi R, Katsuragi S, Takamatsu J, Miyakawa T. Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease. Psychiatry Clin Neurosci. 1997 ; 51 (3). 135-138
47. Kiyota T, Gendelman HE, Weir RA, Higgins EE, Zhang G, Jain M. CCL2 affects beta-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer's disease. Neurobiol Aging. 2013 ; 34 (4). 1060-1068
48. Naert G, Rivest S. Hematopoietic CC-chemokine receptor 2 (CCR2) competent cells are protective for the cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease. Mol Med. 2012 ; 18: 297-313
49. Lee YK, Kwak DH, Oh KW, et al. CCR5 deficiency induces astrocyte activation, Abeta deposit and impaired memory function. Neurobiol Learn Mem. 2009 ; 92 (3). 356-363
50. Kawaguchi-Niida M, Yamamoto T, Kato Y, Inose Y, Shibata N. MCP-1/CCR2 signaling-mediated astrocytosis is accelerated in a transgenic mouse model of SOD1-mutated familial ALS. Acta Neuropathol Commun. 2013 ; 1 (1). 21
51. Lawrence DM, Seth P, Durham L, et al. Astrocyte differentiation selectively upregulates CCL2/monocyte chemoattractant protein-1 in cultured human brain-derived progenitor cells. Glia. 2006 ; 53 (1). 81-91
52. Liao Y, Guan ZZ, Ravid R. Changes of nuclear factor and inflammatory chemotactic factors in brain of patients with Alzheimer's disease. Zhonghua Bing Li Xue Za Zhi. 2011 ; 40 (9). 585-589
53. Westin K, Buchhave P, Nielsen H, Minthon L, Janciauskiene S, Hansson O. CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. PLoS One. 2012 ; 7 (1). e30525
54. Ho L, Zhao W, Dams O'Connor K, et al. Elevated plasma MCP-1 concentration following traumatic brain injury as a potential "predisposition" factor associated with an increased risk for subsequent development of Alzheimer's disease. J Alzheimers Dis. 2012 ; 31 (2). 301-313
55. Xia MQ, Qin SX, Wu LJ, Mackay CR, Hyman BT. Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. Am J Pathol. 1998 ; 153 (1). 31-37
56. Passos GF, Figueiredo CP, Prediger RD, et al. Role of the macrophage inflammatory protein-1alpha/CC chemokine receptor 5 signaling pathway in the neuroinflammatory response and cognitive deficits induced by beta-amyloid peptide. Am J Pathol. 2009 ; 175 (4). 1586-1597
57. Li K, Dai D, Yao L, et al. Association between the macrophage inflammatory protein-l alpha gene polymorphism and Alzheimer's disease in the Chinese population. Neurosci Lett. 2008 ; 433 (2). 125-128
58. Man SM, Ma YR, Shang DS, et al. Peripheral T cells overexpress MIP-1alpha to enhance its transendothelial migration in Alzheimer's disease. Neurobiol Aging. 2007 ; 28 (4). 485-496
59. Cartier L, Hartley O, Dubois-Dauphin M, Krause KH. Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases. Brain Res Brain Res Rev. 2005 ; 48 (1). 16-42
60. Lumpkins K, Bochicchio GV, Zagol B, et al. Plasma levels of the beta chemokine regulated upon activation, normal T cell expressed, and secreted (RANTES) correlate with severe brain injury. J Trauma. 2008 ; 64 (2). 358-361
61. Sharma V, Mishra M, Ghosh S, et al. Modulation of interleukin-1beta mediated inflammatory response in human astrocytes by flavonoids: implications in neuroprotection. Brain Res Bull. 2007 ; 73 (1-3). 55-63
62. Chen CJ, Chen JH, Chen SY, Liao SL, Raung SL. Upregulation of RANTES gene expression in neuroglia by Japanese encephalitis virus infection. J Virol. 2004 ; 78 (22). 12107-12119
63. Tripathy D, Thirumangalakudi L, Grammas P. RANTES upregulation in the Alzheimer's disease brain: a possible neuroprotective role. Neurobiol Aging. 2010 ; 31 (1). 8-16
64. Skuljec J, Sun H, Pul R, et al. CCL5 induces a pro-inflammatory profile in microglia in vitro. Cell Immunol. 2011 ; 270 (2). 164-171
65. Lee JK, Schuchman EH, Jin HK, Bae JS. Soluble CCL5 derived from bone marrow-derived mesenchymal stem cells and activated by amyloid beta ameliorates Alzheimer's disease in mice by recruiting bone marrow-induced microglia immune responses. Stem Cells. 2012 ; 30 (7). 1544-1555
66. Kester MI, van der Flier WM, Visser A, Blankenstein MA, Scheltens P, Oudejans CB. Decreased mRNA expression of CCL5 [RANTES] in Alzheimer's disease blood samples. Clin Chem Lab Med. 2012 ; 50 (1). 61-65
67. Avdoshina V, Biggio F, Palchik G, Campbell LA, Mocchetti I. Morphine induces the release of CCL5 from astrocytes: potential neuroprotective mechanism against the HIV protein gp120. Glia. 2010 ; 58 (13). 1630-1639
68. Avdoshina V, Biggio F, Palchik G, Campbell LA, Mocchetti I. Expression of CXCL8, CXCR1, and CXCR2 in neurons and glial cells of the human and rabbit retina. Invest Ophthalmol Vis Sci. 2008 ; 49 (10). 4578-4589
69. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006 ; 354 (6). 610-621
70. Bonotis K, Krikki E, Holeva V, Aggouridaki C, Costa V, Baloyannis S. Systemic immune aberrations in Alzheimer's disease patients. J Neuroimmunol. 2008 ; 193 (1-2). 183-187
71. Thirumangalakudi L, Yin L, Rao HV, Grammas P. IL-8 induces expression of matrix metalloproteinases, cell cycle and pro-apoptotic proteins, and cell death in cultured neurons. J Alzheimers Dis. 2007 ; 11 (3). 305-311
72. Watson K, Fan GH. Macrophage inflammatory protein 2 inhibits beta-amyloid peptide (1-42)-mediated hippocampal neuronal apoptosis through activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling pathways. Mol Pharmacol. 2005 ; 67 (3). 757-765
73. Ashutosh, Kou W, Cotter R, et al. CXCL8 protects human neurons from amyloid-beta-induced neurotoxicity: relevance to Alzheimer's disease. Biochem Biophys Res Commun. 2011 ; 412 (4). 565-571
74. Horuk R, Martin AW, Wang Z, et al. Expression of chemokine receptors by subsets of neurons in the central nervous system. J Immunol. 1997 ; 158 (6). 2882-2890
75. Xia M, Qin S, McNamara M, Mackay C, Hyman BT. Interleukin-8 receptor B immunoreactivity in brain and neuritic plaques of Alzheimer's disease. Am J Pathol. 1997 ; 150 (4). 1267-1274
76. Liu YJ, Guo DW, Tian L, et al. Peripheral T cells derived from Alzheimer's disease patients overexpress CXCR2 contributing to its transendothelial migration, which is microglial TNF-alpha-dependent. Neurobiol Aging. 2010 ; 31 (2). 175-188
77. Flynn G, Maru S, Loughlin J, Romero IA, Male D. Regulation of chemokine receptor expression in human microglia and astrocytes. J Neuroimmunol. 2003 ; 136 (1-2). 84-93
78. Rostasy K, Egles C, Chauhan A, et al. SDF-1alpha is expressed in astrocytes and neurons in the AIDS dementia complex: an in vivo and in vitro study. J Neuropathol Exp Neurol. 2003 ; 62 (6). 617-626
79. Laske C, Stellos K, Eschweiler GW, Leyhe T, Gawaz M. Decreased CXCL12 (SDF-1) plasma levels in early Alzheimer's disease: a contribution to a deficient hematopoietic brain support?. J Alzheimers Dis. 2008 ; 15 (1). 83-95
80. Laske C, Stellos K, Stransky E, et al. Decreased plasma and cerebrospinal fluid levels of stem cell factor in patients with early Alzheimer's disease. J Alzheimers Dis. 2008 ; 15 (3). 451-460
81. Peng H, Kolb R, Kennedy JE, Zheng J. Differential expression of CXCL12 and CXCR4 during human fetal neural progenitor cell differentiation. J Neuroimmune Pharmacol. 2007 ; 2 (3). 251-258
82. Lazarini F, Tham TN, Casanova P, Arenzana-Seisdedos F, Dubois-Dalcq M. Role of the alpha-chemokine stromal cell-derived factor (SDF-1) in the developing and mature central nervous system. Glia. 2003 ; 42 (2). 139-148
83. Parachikova A, Cotman CW. Reduced CXCL12/CXCR4 results in impaired learning and is downregulated in a mouse model of Alzheimer disease. Neurobiol Dis. 2007 ; 28 (2). 143-153
84. Wang Q, Xu Y, Chen JC, et al. Stromal cell-derived factor 1alpha decreases beta-amyloid deposition in Alzheimer's disease mouse model. Brain Res. 2012 ; 1459: 15-26
85. Raman D, Milatovic SZ, Milatovic D, Splittgerber R, Fan GH, Richmond A. Chemokines, macrophage inflammatory protein-2 and stromal cell-derived factor-1alpha, suppress amyloid beta-induced neurotoxicity. Toxicol Appl Pharmacol. 2011 ; 256 (3). 300-313
86. Rogers JT, Morganti JM, Bachstetter AD, et al. CX3CR1 deficiency leads to impairment of hippocampal cognitive function and synaptic plasticity. J Neurosci. 2011 ; 31 (45). 16241-16250
87. Colton CA, Gilbert DL. Production of superoxide anions by a CNS macrophage, the microglia. FEBS Lett. 1987 ; 223 (2). 284-288
88. Pabon MM, Bachstetter AD, Hudson CE, Gemma C, Bickford PC. CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease. J Neuroinflammation. 2011 ; 8: 9
89. Lee S, Varvel NH, Konerth ME, et al. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am J Pathol. 2010 ; 177 (5). 2549-2562
90. Tuo J, Smith BC, Bojanowski CM, et al. The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age-related macular degeneration. FASEB J. 2004 ; 18 (11). 1297-1299
91. Huang D, Shi FD, Jung S, et al. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. Faseb J. 2006 ; 20 (7). 896-905
92. Kim TS, Lim HK, Lee JY, et al. Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett. 2008l ; 436 (2). 196-200
93. Moynagh PN. The interleukin-1 signalling pathway in astrocytes: a key contributor to inflammation in the brain. J Anat. 2005 ; 207 (3). 265-269
94. Al-Abed Y, VanPatten S. MIF. as a disease target: ISO-1 as a proof-of-concept therapeutic. Future Med Chem. 2011 ; 3 (1). 45-63
95. Bryan KJ, Zhu X, Harris PL, et al. Expression of CD74 is increased in neurofibrillary tangles in Alzheimer's disease. Mol Neurodegener. 2008 ; 3: 13
96. Bacher M, Meinhardt A, Lan HY, et al. MIF expression in the rat brain: implications for neuronal function. Mol Med. 1998 ; 4 (4). 217-230
97. Bacher M, Deuster O, Aljabari B, et al. The role of macrophage migration inhibitory factor in Alzheimer's disease. Mol Med. 2010 ; 16 (3-4). 116-121
98. Yoshiyama Y, Arai K, Oki T, Hattori T. Expression of invariant chain and pro-cathepsin L in Alzheimer's brain. Neurosci Lett. 2000 ; 290 (2). 125-128
99. Sorce S, Bonnefont J, Julien S, et al. Increased brain damage after ischaemic stroke in mice lacking the chemokine receptor CCR5. Br J Pharmacol. 2010 ; 160 (2). 311-321
100. Carreiras MC, Mendes E, Perry MJ, Francisco AP, Marco-Contelles J. The multifactorial nature of Alzheimer's disease for developing potential therapeutics. Curr Top Med Chem. 2013 ; 13 (15). 1745-1770
101. Lambert JC, Grenier-Boley B, Chouraki V, et al. Implication of the immune system in Alzheimer's disease: evidence from genome-wide pathway analysis. J Alzheimers Dis. 2010 ; 20 (4). 1107-1118
102. Galimberti D, Schoonenboom N, Scarpini E, Scheltens P. Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients. Ann Neurol. 2003 ; 53 (4). 547-548
103. Viola A, Luster AD. Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol. 2008 ; 48: 171-197
104. Naert G, Rivest S. CC chemokine receptor 2 deficiency aggravates cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease. J Neurosci. 2011 ; 31 (16). 6208-6220
105. El Khoury J, Toft M, Hickman SE, et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med. 2007 ; 13 (4). 432-438
106. Mandrekar S, Jiang Q, Lee CY, Koenigsknecht-Talboo J, Holtzman DM, Landreth GE. Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J Neurosci. 2009 ; 29 (13). 4252-4562
107. Naert G, Rivest S. The role of microglial cell subsets in Alzheimer's disease. Curr Alzheimer Res. 2011 ; 8 (2). 151-155
108. Magga J, Savchenko E, Malm T, et al. Production of monocytic cells from bone marrow stem cells: therapeutic usage in Alzheimer's disease. J Cell Mol Med. 2012 ; 16 (5). 1060-1073
109. Phillips RJ, Lutz M, Premack B. Differential signaling mechanisms regulate expression of CC chemokine receptor-2 during monocyte maturation. J Inflamm (Lond). 2005 ; 2: 14
110. Chen Y, Green SR, Ho J, Li A, Almazan F, Quehenberger O. The mouse CCR2 gene is regulated by two promoters that are responsive to plasma cholesterol and peroxisome proliferator-activated receptor gamma ligands. Biochem Biophys Res Commun. 2005 ; 332 (1). 188-193
111. Roy A, Kolattukudy PE. Monocyte chemotactic protein-induced protein (MCPIP) promotes inflammatory angiogenesis via sequential induction of oxidative stress, endoplasmic reticulum stress and autophagy. Cell Signal. 2012 ; 24 (11). 2123-2131
112. Kolattukudy PE, Niu J. Inflammation, endoplasmic reticulum stress, autophagy, and the monocyte chemoattractant protein-1/CCR2 pathway. Circ Res. 2012 ; 110 (1). 174-189
113. Niu J, Wang K, Graham S, Azfer A, Kolattukudy PE. MCP-1-induced protein attenuates endotoxin-induced myocardial dysfunction by suppressing cardiac NF-small ka, CyrillicB activation via inhibition of Ismall ka, CyrillicB kinase activation. J Mol Cell Cardiol. 2011 ; 51 (2). 177-186
114. www.tocris.com/pharmacologicalBrowser.php?, C.R.A., 2013.
115. Rosi S, Pert CB, Ruff MR, McGann-Gramling K, Wenk GL. Chemokine receptor 5 antagonist D-Ala-peptide T-amide reduces microglia and astrocyte activation within the hippocampus in a neuroinflammatory rat model of Alzheimer's disease. Neuroscience. 2005 ; 134 (2). 671-676
116. Al-Abed Y, Dabideen D, Aljabari B, et al. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem. 2005 ; 280 (44). 36541-3654